Pictet Asset Management Holding SA Has $227.45 Million Holdings in Zoetis Inc. $ZTS

Pictet Asset Management Holding SA trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 20.0% during the first quarter, Holdings Channel.com reports. The firm owned 1,924,600 shares of the company’s stock after selling 481,023 shares during the period. Pictet Asset Management Holding SA’s holdings in Zoetis were worth $227,450,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Global Wealth Strategies & Associates bought a new stake in Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $30,000. Finally, Elyxium Wealth LLC purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, and others, announced or promoted class-action claims against Zoetis, increasing legal overhang and sentiment pressure on the stock.
• Neutral Sentiment: Zoetis also said it will host a webcast and conference call on August 6, 2026 to discuss second-quarter results, which may provide a more fundamental update for investors. Article Title

Zoetis Price Performance

NYSE ZTS opened at $76.05 on Friday. The company has a market cap of $31.88 billion, a PE ratio of 12.61, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $161.77. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm’s 50-day simple moving average is $88.70 and its two-hundred day simple moving average is $110.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 11,650 shares of company stock valued at $886,384 over the last three months. Company insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZTS. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. UBS Group lowered their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $133.08.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.